Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
出版年份 2023 全文链接
标题
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
作者
关键词
-
出版物
BIODRUGS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-13
DOI
10.1007/s40259-023-00626-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Computational and artificial intelligence-based methods for antibody development
- (2023) Jisun Kim et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework
- (2023) Beate Bittner Expert Opinion on Drug Delivery
- High concentration formulation developability approaches and considerations
- (2023) Jonathan Zarzar et al. mAbs
- Nothing about us should be without us
- (2023) Maria Piggin Lancet Haematology
- Patients as research partners in preference studies: learnings from IMI-PREFER
- (2023) Meredith Y. Smith et al. Research Involvement and Engagement
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tutorial: Statistical analysis and reporting of clinical pharmacokinetic studies
- (2022) Ann‐Cathrine Dalgård Dunvald et al. CTS-Clinical and Translational Science
- Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making
- (2022) Rajanikanth Madabushi et al. PHARMACEUTICAL RESEARCH
- Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
- (2022) Emmanuel Donnadieu et al. Journal for ImmunoTherapy of Cancer
- Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
- (2022) Erin K. McCreary et al. JAMA Network Open
- Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.
- (2022) Matias Rodrigo Chacon et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
- (2022) Romy Mosch et al. Frontiers in Immunology
- Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up
- (2022) Mustafa N. Yenerel et al. ADVANCES IN THERAPY
- A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
- (2022) Conor McCloskey et al. Pharmacoeconomics-Open
- Development of Therapeutic Proteins for a New Subcutaneous Route of Administration after the Establishment of Intravenous Dosages: A Systematic Review
- (2022) Zhenhua Xu et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Modeling large-volume subcutaneous injection of monoclonal antibodies with anisotropic porohyperelastic models and data-driven tissue layer geometries
- (2022) Mario de Lucio et al. Journal of the Mechanical Behavior of Biomedical Materials
- P6 EMA/EUnetHTA Qualification of the IMI PREFER Patient Preference Framework and Points to Consider for Method Selection: Key Experiences, Outcomes, Value and Implications
- (2022) L Barbier et al. VALUE IN HEALTH
- Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
- (2021) Nicole L. Jarvi et al. BIODRUGS
- Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice
- (2021) Issam S. Hamadeh et al. Clinical Lymphoma Myeloma & Leukemia
- Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
- (2021) Yu Tang et al. Pharmaceutics
- Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease
- (2021) Zhigang Wang et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Evaluation of Large Volume Subcutaneous Injection Tissue Effects, Pain, and Acceptability in Healthy Adults
- (2021) Wendy D Woodley et al. CTS-Clinical and Translational Science
- Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
- (2021) Joyce O'Shaughnessy et al. EUROPEAN JOURNAL OF CANCER
- The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018
- (2021) Stephen J. Richards et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
- (2021) Mary Slavcev et al. ClinicoEconomics and Outcomes Research
- Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma
- (2021) E. Bridget Kim et al. BLOOD
- Model‐Informed Drug Development Approaches to Assist New Drug Development in the COVID‐19 Pandemic
- (2021) Ye Xiong et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Systematic Review of Device Parameters and Design of Studies Bridging Biologic-Device Combination Products Using Prefilled Syringes and Autoinjectors
- (2020) Ping Hu et al. AAPS Journal
- Why Do the Majority of Submissions for Bridging from a Prefilled Syringe to an Autoinjector Include Bioequivalence Studies in Order to Demonstrate Comparability?
- (2020) William J. Lambert AAPS Journal
- Injectable Combination Product Development: Facilitating Risk-Based Assessments for Efficiency and Patient Centric Outcomes
- (2020) Fran DeGrazio et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?
- (2020) Chiara Whichello et al. HEALTH POLICY
- The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
- (2020) Anna Vaisman-Mentesh et al. Frontiers in Immunology
- Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects
- (2020) Wendy D Woodley et al. CTS-Clinical and Translational Science
- Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
- (2020) Antoinette R Tan et al. LANCET ONCOLOGY
- Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
- (2020) Anja St Clair-Jones et al. Rheumatology and Therapy
- Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma
- (2019) Saad Z. Usmani et al. BLOOD
- Helping patients help themselves: A systematic review of self-management support strategies in primary health care practice
- (2019) Sarah Dineen-Griffin et al. PLoS One
- The importance of early identification of infusion-related reactions to monoclonal antibodies
- (2019) Macarena C Cáceres et al. Therapeutics and Clinical Risk Management
- Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers
- (2019) Di Bei et al. CANCER SCIENCE
- Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
- (2018) A. Brekkan et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model
- (2018) Ninad Varkhede et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Adverse events in patients in home healthcare: a retrospective record review using trigger tool methodology
- (2018) Kristina Görel Ingegerd Schildmeijer et al. BMJ Open
- Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
- (2018) Beate Bittner et al. BIODRUGS
- Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants?
- (2018) Satish K. Singh et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Infusion-related reactions to rituximab: frequency, mechanisms and predictors
- (2018) Franciane Paul et al. Expert Review of Clinical Immunology
- Roadmap and strategy for overcoming infusion reactions to nanomedicines
- (2018) Janos Szebeni et al. Nature Nanotechnology
- Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins
- (2017) Lora Hamuro et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Evaluation of dosing strategy for pembrolizumab for oncology indications
- (2017) Tomoko Freshwater et al. Journal for ImmunoTherapy of Cancer
- Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
- (2016) M. Rummel et al. ANNALS OF ONCOLOGY
- Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation
- (2016) Khilna Patel et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
- (2015) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
- (2015) Sarit Assouline et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
- (2015) Angelica L. Quartino et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Model-based clinical drug development in the past, present and future: a commentary
- (2014) Holly Kimko et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
- (2014) Antonio Salar et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
- (2014) Andrew Davies et al. LANCET ONCOLOGY
- A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design
- (2014) Jasmine P Davda et al. mAbs
- Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
- (2014) Alan Kivitz et al. ARTHRITIS CARE & RESEARCH
- The Antibody Drug Absorption Following Subcutaneous or Intramuscular Administration and Its Mathematical Description by Coupling Physiologically Based Absorption Process with the Conventional Compartment Pharmacokinetic Model
- (2013) Liang Zhao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- The questionable use of unequal allocation in confirmatory trials
- (2013) S. P. Hey et al. NEUROLOGY
- Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen
- (2012) B. Bittner et al. ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
- Home medication management practices and associated factors among patients with selected chronic diseases in a community pharmacy in Uganda
- (2012) Joan N Kalyango et al. BMC HEALTH SERVICES RESEARCH
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer
- (2012) Chris Wynne et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
- (2012) Gustavo Ismael et al. LANCET ONCOLOGY
- Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis
- (2012) Jai S Perumal et al. Multiple Sclerosis Journal
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
- (2011) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now